Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020

Kimberly Davies, MD^{1,*}; Matthew Barth, MD^{2,*}; Saro Armenian, DO, MPH³; Anthony N. Audino, MD^{4,*}; Phillip Barnette, MD⁵; Branko Cuglievan, MD⁶; Hilda Ding, MD⁷; James B. Ford, DO⁸; Paul J. Galardy, MD⁹; Rebecca Gardner, MD¹⁰; Rabi Hanna, MD¹¹; Robert Hayashi, MD¹²; Alexandra E. Kovach, MD^{13,*}; Andrea Judit Machnitz, MD¹⁴; Kelly W. Maloney, MD¹⁵; Lianna Marks, MD¹⁶; Kristin Page, MD¹⁷; Anne F. Reilly, MD, MPH¹⁸; Joanna L. Weinstein, MD¹⁹; Ana C. Xavier, MD²⁰; Nicole R. McMillian, MS, CHES²¹; and Deborah A. Freedman-Cass, PhD²¹

ABSTRACT

Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the treatment is complex, and patients may have many complicated supportive care issues. The NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas provide guidance regarding pathology and diagnosis, staging, initial treatment, disease reassessment, surveillance, therapy for relapsed/refractory disease, and supportive care for clinicians who treat sporadic pediatric BL and DLBCL.

J Natl Compr Canc Netw 2020;18(8):1105–1123
doi: 10.6004/jnccn.2020.0036

NCCN CATEGORIES OF EVIDENCE AND CONSENSUS

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PLEASE NOTE

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network[®] (NCCN[®]) makes no representations or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

The complete NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas are not printed in this issue of JNCCN but can be accessed online at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Pediatric Aggressive Mature B-Cell Lymphomas Panel

At the beginning of each NCCN Guidelines Panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Pediatric Aggressive Mature B-Cell Lymphomas Panel members can be found on page 1123. (The most recent version of these guidelines and accompanying disclosures are available at NCCN.org.)

The complete and most recent version of these guidelines is available free of charge at NCCN.org.

¹Dana-Farber/Boston Children's Cancer and Blood Disorders Center; ²Roswell Park Comprehensive Cancer Center; ³City of Hope National Medical Center; ⁴The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; ⁵Huntsman Cancer Institute at the University of Utah; ⁶The University of Texas MD Anderson Cancer Center; ⁷UCSD Rady Children's Hospital/UC San Diego Moores Cancer Center; ⁸Fred & Pamela Buffett Cancer Center; ⁹Mayo Clinic Cancer Center; ¹⁰Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; ¹¹Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; ¹²Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; ¹³Vanderbilt-Ingram Cancer Center; ¹⁴The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; ¹⁵Children's Hospital of Colorado/University of Colorado Cancer Center; ¹⁶Stanford Cancer Institute; ¹⁷Duke Cancer Institute; ¹⁸Abramson Cancer Center at the University of Pennsylvania; ¹⁹Robert H. Lurie Comprehensive Cancer Center of Northwestern University; ²⁰Children's of Alabama/O'Neal Comprehensive Cancer Center at UAB; and ²¹National Comprehensive Cancer Network

*Discussion Writing Committee Member.

See JNCCN.org for supplemental online content.

PEDIATRIC AGGRESSIVE MATURE B-CELL LYMPHOMA^a DIAGNOSIS^e

Pediatric Burkitt lymphoma and Pediatric diffuse large B-cell lymphoma (DLBCL) including adolescent and young adult (AYA) patients treated in the pediatric oncology setting^{b,c,d}

- **Biopsy**
 - ▶ Excisional or incisional biopsy of most accessible site is preferred.
 - ▶ A core needle biopsy is less optimal but can be used in circumstances when a lymph node or tumor mass is not easily accessible for excisional or incisional biopsy. If core biopsies are to be used for diagnosis, the cores must be of sufficient size and number to allow for evaluation of morphology, tumor architecture, and all necessary ancillary studies (immunohistochemistry [IHC], flow cytometry, karyotype, and FISH for major translocations as applicable).
 - ▶ A fine-needle aspiration (FNA) biopsy alone is not suitable for the initial diagnosis of pediatric lymphoma.
 - ▶ Place fresh specimen in saline, not formalin, ensuring viable diagnostic tissue for the pathologist.
- **Pathology^f**
 - ▶ Morphologic and immunohistochemistry review as clinically indicated.
 - ▶ Touch preparation for cytologic examination is recommended.

Additional Diagnostic Testing (See PBCL-2)

^aPediatric Burkitt lymphoma and DLBCL are curable, but the treatment is complex. It is preferred that treatment occur at centers with expertise in the management of these diseases.

^bRecommendations for the management of primary mediastinal B-cell lymphoma (PMBL) are not included in these guidelines. For PMBL first-line therapy recommendations, see the adult NCCN Guidelines for B-Cell Lymphomas[†] (BCEL-B, page 1 of 3).

^cThe Pediatric Aggressive Mature B-Cell Lymphomas panel considers "pediatric" to include any patient aged 18 years and younger, and AYA patients older than 18 years of age, who are treated in a pediatric oncology setting. Practice patterns vary with regards to AYA patients from center to center in terms of whether AYA patients (defined by the National Cancer Institute as <39 years of age) with mature B-cell lymphoma are treated primarily by pediatric or adult oncologists. These guidelines are intended to apply to AYA patients with good organ function treated in a pediatric oncology setting. AYA patients treated in an adult oncology setting should be treated as per the adult NCCN Guidelines for B-Cell Lymphomas[†].

^dAlso see the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology[†].

^eDefinitive diagnosis may not be feasible before beginning treatment. If the patient is very sick, morphology and flow cytometry are the minimum methodologies from which to yield diagnostic information to begin treatment. Malignant fluid cytology and flow cytometry may suffice.

^fSee Principles of Pathology (PBCL-A^{*}).

[†]To view the most recent version of these guidelines, visit NCCN.org.

^{*}Available in the supplemental online content at JNCCN.org.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-1

Overview

An estimated 16,850 children and adolescents aged 19 years or younger will be diagnosed with cancer in the United States in 2020, and 1,730 will die of the disease.¹ In those aged 14 or younger, non-Hodgkin lymphoma (NHL) accounts for 5% of cancers, whereas in adolescents aged 15 to 19 years, NHL accounts for 7%.¹ The 5-year relative survival rates for patients with NHL in these age groups are 91% and 88%, respectively.¹ Pediatric aggressive mature B-cell lymphomas are the most common NHL types in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).²

Three epidemiologic variants of BL exist: endemic, immunodeficiency-associated, and sporadic.³ The endemic form of BL is associated with Epstein-Barr virus (EBV) infection in approximately 95% of cases and occurs mainly in equatorial Africa, South America, Turkey, and Papua New Guinea, with presentation most commonly in the jaw, orbit, mesentery, and central nervous system (CNS). It is also often associated with malaria infection.^{4,5} In fact, endemic BL accounts for as many as 70% of childhood cancers in equatorial Africa, where malaria is highly prevalent and

intense.⁶ Immunodeficiency-associated disease occurs primarily in people living with HIV, in whom it may be the initial AIDS-defining condition. Up to 70% of these patients test positive for EBV. Sporadic cases, about 15% of which are EBV+, mainly occur in North America and Europe and commonly present in the abdomen, lymph nodes, bone marrow, or cerebrospinal fluid (CSF). Endemic DLBCL has also been described and may be associated with EBV, hepatitis B virus (HBV), and/or John Cunningham virus infection.⁷⁻⁹ These guidelines do not address endemic or immunodeficiency-associated BL or DLBCL at this time.

This discussion summarizes the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Aggressive Mature B-Cell Lymphomas. These guidelines are intended to provide guidance regarding pathology and diagnosis, staging, initial treatment, disease reassessment, surveillance, therapy for relapsed/refractory disease, and supportive care for clinicians who treat sporadic pediatric BL and DLBCL. These guidelines do not include recommendations for the management of patients with primary mediastinal B-cell lymphoma, who should be treated as per the adult NCCN Guidelines

ADDITIONAL DIAGNOSTIC TESTING^f

ESSENTIAL

- Adequate immunophenotyping to establish diagnosis^{g,h,i}
 - ▶ Immunohistochemistry panel: Ki-67, BCL-2, BCL-6, CD3, CD10, CD20, MUM1
 - ▶ Flow cytometry: Surface kappa/lambda, CD3, CD5, CD10, CD19, CD20, CD45
 - ▶ Fluorescence in situ hybridization (FISH): C-MYC rearrangement^l

USEFUL UNDER CERTAIN CIRCUMSTANCES

- Karyotype: t(8;14) or variants t(2;8) or t(8;22) and to identify additional chromosomal abnormalities
- FISH for BCL-2 and BCL-6 rearrangements^k
- FISH or single nucleotide polymorphism (SNP) array for 11q aberration
- EBER-ISH^l
- C-MYC immunohistochemistry
- TdT immunohistochemistry or flow cytometry
- Clonality testing by polymerase chain reaction (PCR) for immunoglobulin gene rearrangement

Workup
(See PBCL-3)

^fSee Principles of Pathology (PBCL-A*).

^gTypical immunophenotype of Burkitt lymphoma: slg+, CD10+, CD20+, TdT-, Ki-67+ (≥95%), BCL2-, BCL6+, simple karyotype with MYC rearrangement as sole abnormality. Typical immunophenotype of DLBCL: slg+, CD20+, TdT-, Ki-67 variably high, CD10+/-, BCL6+/-, MUM1+/-, BCL2+/-, variable karyotype with C-MYC, BCL6, BCL2, and/or other IgH rearrangements.

^hSee Use of Immunophenotyping/Genetic Testing in Differential Diagnosis of Mature B-Cell and NK/T-Cell Neoplasms (NHODG-A) in the NCCN Guidelines for B-Cell Lymphomas[†].

ⁱIf flow cytometry is initially performed, IHC for selected markers (BCL2 and Ki-67) can supplement the flow results.

^jOn formalin-fixed, paraffin-embedded tissue, MYC rearrangement is best assessed by MYC break apart probe to capture any partner gene.

^kDouble- and triple-hit lymphomas are currently not well described or studied in the pediatric population but FISH for BCL-2 and BCL-6 rearrangements may be considered in the AYA population.

^lEBER-ISH is most applicable in endemic Burkitt lymphoma or immunocompromised clinical settings for either Burkitt lymphoma or DLBCL.

[†]To view the most recent version of these guidelines, visit NCCN.org.

*Available in the supplemental online content at JNCCN.org.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-2

for B-Cell Lymphomas (available at NCCN.org). Pediatric BL and DLBCL are highly aggressive but curable, and the treatment is complex. It is preferred that treatment occur at centers with expertise in the management of these diseases.

The Pediatric Aggressive Mature B-Cell Lymphoma Panel considers *pediatric* to include any patient aged 18 years and younger, and adolescent and young adult (AYA) patients older than age 18 years who are treated in a pediatric oncology setting. Practice patterns vary from center to center in terms of whether AYA patients (defined by the National Cancer Institute as <39 years of age) with mature B-cell lymphoma are treated primarily by pediatric or adult oncologists. These guidelines are intended to apply to all pediatric patients and to AYA patients treated in a pediatric oncology setting who have good organ function. AYA patients treated in an adult oncology setting and those without good organ function should be treated as per the adult NCCN Guidelines for B-Cell Lymphomas (available at NCCN.org).

Medical practitioners should note that unusual patient scenarios (presenting in <5% of patients) are not specifically discussed in these guidelines and that all

recommendations are classified as category 2A if not otherwise noted. Although the guidelines are believed to represent the optimal treatment strategy, the panel believes that, when appropriate, patients should preferentially be included in a clinical trial over standard or accepted therapy.

Literature Search Criteria and Guidelines Update Methodology

Before initial development of these NCCN Guidelines, an electronic search of the PubMed database was performed to obtain key literature using the following search terms: pediatric Burkitt lymphoma and pediatric diffuse large lymphoma. The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.¹⁰ The search results were narrowed by selecting studies in humans published in English.

The data from key PubMed articles and articles from additional sources deemed as relevant to these guidelines and discussed by the panel have been included in this version of the discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations

**WORKUP
ESSENTIAL**

- History, including personal and family history of immunodeficiency
- Physical exam, with attention to lymph nodes, Waldeyer's ring, liver and spleen size, effusions, ascites, neurologic signs
- Evaluation for signs or symptoms of ureteral obstruction
- Evaluation for signs or symptoms of spinal cord compression or cranial neuropathy
- Performance status (Lansky/Karnofsky)
- Labs
 - CBC with differential
 - Electrolytes, calcium, phosphorus, blood urea nitrogen (BUN), creatinine, uric acid
 - Lactate dehydrogenase (LDH)
 - Aspartate transaminase (AST), alanine transaminase (ALT), bilirubin, albumin
 - Hepatitis B testing (HBcAb, HBsAb, HBsAg)
 - Consider HIV testing, if indicated
 - Consider G6PD testing for male patients^m
 - Pregnancy test for females of childbearing age
- Bilateral bone marrow aspirate and biopsy
- Lumbar puncture
 - Cell count & differential
 - Cytology, including total nucleated cell count and morphologic review of cytospin
- Imaging
 - Chest x-ray posteroanterior (PA)/lateral and abdominal ultrasound (if cross-sectional imaging not available)
 - CT chest/abdomen/pelvis with contrast or CT chest/MR abdomen and pelvis
 - FDG-PET/CT or FDG-PET/MRI, if available (do not delay treatment to obtain)ⁿ
- Echocardiogram (ECHO) or multigated acquisition (MUGA) scan
- Fertility counseling recommended; fertility preservation as clinically appropriate

→ See Risk
Group
Definitions
(PBCL-4)

USEFUL UNDER CERTAIN CIRCUMSTANCES

- MRI of the head, if clinically indicated
- MRI of the spine, if clinically indicated
- MRI or CT of the neck, if evidence of neck disease
- Flow cytometry of cerebrospinal fluid (CSF)^o
- Flow cytometry, FISH for MYC rearrangement, and immunohistochemistry of bone marrow^p

^mSee Principles of Supportive Care (PBCL-D*).

ⁿObtaining a PET/CT or PET/MRI does not exclude the need for full diagnostic quality high-resolution CT or MRI.

^oFlow cytometry of CSF samples is not routinely recommended, but may be useful at the pathologist's discretion.

^pFor low-level or morphologically indeterminate involvement.

*Available in the supplemental online content at JNCCN.org.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-3

for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion. The complete details of the development and update of the NCCN Guidelines are available on the NCCN website (NCCN.org).

Initial Presentation

Patients with DLBCL and BL may present with fever, chills, night sweats, unexplained/unintentional weight loss, painless regional or diffuse lymphadenopathy, fatigue, bone pain, and/or irritability. Extranodal involvement on presentation is common.¹¹ Oncologic emergencies may also be the reason for initial presentation, because of the potential for complications of rapid tumor growth (ie, tumor lysis syndrome, superior vena cava syndrome, respiratory compromise, spinal cord compression). In addition, patients with abdominal tumors may have a history of abdominal pain/swelling, poor appetite/early satiety, constipation, and/or nausea/emesis.¹² Intrathoracic masses can cause coughing, dyspnea, wheezing, stridor, chest pain, and/or reduced endurance. Tumors in the head and neck may be associated with swollen glands; swelling in the neck, jaw, gingival area, or maxilla; difficulty

swallowing; choking; and/or vision changes. Finally, CNS involvement can lead to bladder or bowel dysfunction, lower extremity weakness, and/or headaches.

Pathology and Diagnosis

Excisional or incisional biopsy of the most accessible site is preferred, with fresh biopsy tissue sent to pathology in saline to ensure viable diagnostic tissue. Touch preparation for cytologic examination is recommended, and morphologic and immunohistochemistry review should be performed as clinically indicated.¹³ Immunophenotyping and cytogenetics are essential to establish a diagnosis of BL or DLBCL. However, definitive diagnosis may not be feasible before beginning treatment. Morphology and flow cytometry are the minimum methodologies from which to yield diagnostic information to begin treatment, especially if the patient is very sick. Malignant fluid cytology and flow cytometry may suffice.

Morphology

BL and DLBCL are morphologically distinct.^{14,15} Cytologically, BL lymphoid cells are intermediate in size (similar in size to a histiocyte nucleus) and have round

RISK GROUP DEFINITIONS^q

Group Classification ^r		Initial therapy
Group A	Completely resected stage I or Completely resected abdominal stage II	See PBCL-5
Group B	All cases not eligible for Group A or Group C (unresected stage I and non-abdominal stage II, stage III and non-CNS stage IV with <25% bone marrow involvement)	See PBCL-6 and PBCL-7
Group C	Any CNS involvement ^s and/or Bone marrow involvement (≥25% lymphoma cells)	See PBCL-8

^qAdapted with permission from Cairo MS, Gerrard M, Spoto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. *Blood* 2007;109:2736-2743.

^rFor Staging, see ST-1.

^sThe central nervous system (CNS) is considered involved if one or more of the following applies:

- Any lymphoma cells by cytology in CSF
- Any CNS tumor mass by imaging
- Cranial nerve palsy (if not explained by extracranial tumor)
- Clinical spinal cord compression
- Parameningeal extension: cranial and/or spinal

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-4

nuclei, relatively coarse chromatin with multiple small nucleoli, and scant cytoplasm. Clear cytoplasmic vacuoles may be seen on Wright Giemsa-stained touch preparations. The cells of DLBCL are large with variable nuclear contours, condensed to vesicular chromatin, single or multiple nucleoli, and scant to moderately abundant cytoplasm. Cytoplasmic vacuoles are not typically present.

Tissue sections of BL and DLBCL are also distinctive.¹⁴⁻¹⁶ BL is composed of patternless sheets of lymphoid cells that appear to mold to one another (pseudo-cohesion). Scattered histiocytes with apoptotic debris in the cytoplasm (tingible-body macrophages) confer the so-called “starry sky” appearance indicative of high cell turnover. Pediatric BL tends to show little morphologic variation. The architecture of DLBCL also shows sheet-like growth, but the significant nuclear pleomorphism and scant to abundant cytoplasm confer a lighter color at low magnification. “Starry sky” appearance is generally not prominent.

Immunophenotyping

Immunophenotyping to establish a diagnosis of BL or DLBCL is performed by immunohistochemistry and flow

cytometry.^{14,15} As mature B-cell lymphomas, BLs and DLBCLs express surface immunoglobulin and the surface B-cell marker CD20. All BLs and most DLBCLs also express CD10, a germinal center B-cell marker. They are both typically negative for terminal deoxynucleotidyl transferase, a marker of cellular immaturity, and negative for CD3, a T-cell marker. BLs are negative for BCL2 and positive for BCL6. Greater than or equal to 95% of BLs are Ki-67-positive. For DLBCL, expression of Ki-67, BCL2, and BCL6 is variable.

Cytogenetics

Fluorescence in situ hybridization for *C-MYC* rearrangement is also recommended for diagnosis of BL and DLBCL. BLs generally exhibit a simple karyotype, with *MYC* translocation involving an immunoglobulin gene as their sole abnormality.¹⁷⁻²⁰ The karyotype of DLBCL is variable and may include rearrangements of *MYC*, *BCL6*, *BCL2*, and/or other *IgH* rearrangements.²¹⁻²⁴ Double- and triple-hit lymphomas (ie, those with *MYC* rearrangement that also have *BCL2* and/or *BCL6* rearrangements) are rare in the pediatric BL and DLBCL populations, but may be more common in AYA patients.²⁵⁻²⁹

^mSee Principles of Supportive Care (PBCL-D*).

^tThe Berlin-Frankfurt-Münster (BFM) group has equivalent regimens that are not standardly used in North America.

^uRadiation therapy rarely has a role in pediatric aggressive mature B-cell lymphomas due to the rapid lysis of tumor to chemotherapy and the avoidance of long-term side effects in children.

^vSee Principles of Systemic Therapy (PBCL-B*).

^wReassess sites of original disease with radiologic studies as indicated (abdominal ultrasound, chest/abdominal/pelvic CT with contrast, and/or MRI of the head, neck, abdomen, and/or pelvis).

^xFDG-PET/CT or FDG-PET/MRI may be considered, if not obtained as part of diagnostic evaluation. FDG-PET should not replace imaging with contrast-enhanced diagnostic quality CT or MRI. A patient's therapy should not be escalated based on FDG-PET alone. If a residual lesion is FDG-PET negative (Deauville 1, 2 or 3; See PBCL-C 2 of 2), biopsy is not necessary. In the absence of clinical concern, FDG-PET does not need to be repeated once it is negative. False negatives are unusual. False positives are common.

^ySee Response Criteria (PBCL-C).

^zResidual mass should be biopsied prior to categorizing it as residual disease.

*Available in the supplemental online content at JNCCN.org.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-5

The recommended treatment of double- and triple-hit lymphomas in the pediatric patient population is the same as for other BLs and DLBCLs in the pediatric age group. Therefore, the treatment recommendations in these guidelines apply to double- and triple-hit lymphomas.

Demonstration of EBV association using EBV-encoded RNA by in situ hybridization may be performed in BL and DLBCL, if indicated by a history or suspicion of immunodeficiency. Historically, EBV expression was predominantly seen in the endemic form of BL. However, EBV-positive DLBCL and BL can be seen in pediatric patients without recognized immunodeficiency.^{15,30,31} Some evidence suggests that EBV positivity in sporadic BL may be associated with older age at diagnosis and higher incidence of nodal involvement.³²

Burkitt-Like Lymphoma

In the absence of a *C-MYC* rearrangement, the diagnosis of Burkitt-like lymphoma with 11q aberration may be pursued.^{33,34} Burkitt-like lymphomas have a more complex karyotype than BL and are sometimes seen in the posttransplant setting.^{35,36} The epidemiology and natural history of this recently recognized entity has yet to be

defined, but pediatric cases have been described.^{37–39} The recommended treatment of Burkitt-like lymphoma is the same as for BL.

Workup

Workup for patients with a diagnosis of BL or DLBCL is delineated in the guidelines. It includes history and physical exam, laboratory analysis, bilateral bone marrow aspirate and biopsy, lumbar puncture, and imaging. FDG-PET/CT or FDG-PET/MRI is recommended if available.⁴⁰ However, treatment should not be delayed to obtain this scan, and FDG-PET does not exclude the need for full diagnostic quality, high-resolution CT or MRI (also see “Response Assessment,” page 1116). Information regarding bone marrow and CNS involvement and distant spread is important for staging (see “Staging and Risk Group Classification,” next section). CNS positivity is found in approximately 9% and 3% of pediatric patients with BL and DLBCL, respectively.^{41,42}

In addition, a baseline echocardiogram or multi-gated acquisition scan is recommended, and fertility counseling should be offered with fertility preservation as clinically appropriate.

*Available in the supplemental online content at JNCCN.org.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-6

Staging and Risk Group Classification

Historically, the Murphy/St. Jude Childhood NHL staging classification, published in 1980, was used for staging of pediatric BL and DLBCL.⁴³ A revised system, the international pediatric NHL staging system (IPNHLSS), was published in 2015.⁴⁴ It addresses some limitations of the original system by including newer histologic entities; recognizing frequent skin, bone, kidney, ovarian, and other organ involvement; and accounting for improved detection of bone marrow and CNS involvement and distant spread. The panel supports use of the revised IPNHLSS, as detailed in the algorithm.

CNS Positivity

Patients with CNS involvement have stage IV disease. The CNS is considered involved if one or more of the following applies:

- Any lymphoma cells by cytology in CSF
- Any CNS tumor mass by imaging
- Cranial nerve palsy (if not explained by extracranial tumor)
- Clinical spinal cord compression
- Parameningeal extension: cranial and/or spinal

Bone Marrow Positivity

Bone marrow involvement is defined by morphologic evidence of ≥5% lymphoma cells in a bone marrow aspirate.⁴⁴ Patients with bone marrow involvement have stage IV disease. However, patients with any detectable bone marrow involvement should not be considered for Group A or Pediatric Oncology Group (POG) 9219 therapy.

Risk Groups

The panel's treatment recommendations for pediatric patients with BL and DLBCL are based on the risk group classification used in the French-American-British/Lymphoma Malignancy B group FAB/LMB96 trial.⁴⁵

- Group A includes patients with completely resected stage I or completely resected abdominal stage II disease.
- Group C includes patients with CNS involvement and/or with ≥25% lymphoma cells in the bone marrow.
- Group B includes all patients not eligible for Group A or C.

^mSee Principles of Supportive Care (PBCL-D*).

^tThe BFM has equivalent regimens that are not standardly used in North America.

^uRadiation therapy rarely has a role in pediatric aggressive mature B-cell lymphomas due to the rapid lysis of tumor to chemotherapy and the avoidance of long-term side effects in children.

^vSee Principles of Systemic Therapy (PBCL-B*).

^xFDG-PET/CT or FDG-PET/MRI may be considered, if not obtained as part of diagnostic evaluation. FDG-PET should not replace imaging with contrast-enhanced diagnostic quality CT or MRI. A patient's therapy should not be escalated based on FDG-PET alone. If a residual lesion is FDG-PET negative (Deauville 1, 2, or 3; See PBCL-C 2 of 2), biopsy is not necessary. In the absence of clinical concern, FDG-PET does not need to be repeated once it is negative. False negatives are unusual. False positives are common.

^ySee Response Criteria (PBCL-C).

^zResidual mass should be biopsied prior to categorizing it as residual disease.

⁹⁹Any Stage III patient with LDH > 2 times ULN, and all non-CNS Stage IV patients with <25% bone marrow involvement.

^{hh}Reassess sites of original disease with radiologic studies as indicated (abdominal ultrasound, chest/abdominal/pelvic CT with contrast, and/or MRI of the head, neck, abdomen, and/or pelvis). Bone marrow and CSF studies should also be performed if bone marrow or CSF were initially involved.

*Available in the supplemental online content at JNCCN.org.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-7

- Group B is further divided into low risk and high risk:
- To qualify as low-risk Group B, the patient must have incompletely resected stage I or II disease or stage III disease if lactate dehydrogenase (LDH) is ≤ 2 times the upper limit of normal.
- High-risk Group B includes patients with CNS-negative stage IV disease and bone marrow involvement of <25% and includes patients with stage III disease and LDH >2 times the upper limit of normal.

Initial Treatment

Systemic therapy is the mainstay of initial treatment of patients with BL or DLBCL based on many clinical trials, including those discussed subsequently. Several cooperative groups have been instrumental in establishing the standard regimens for these patients, including the Children's Oncology Group (COG), the POG, the French Society of Pediatric Oncology, the Children's Cancer Group, the United Kingdom Children's Cancer Study Group, and the German Berlin-Frankfurt-Münster (BFM) group.

The intensive, multiagent regimens used as initial therapy are highly effective for most patients. For example,

in the FAB/LMB96 study (see next section), only 2.5% of patients had refractory disease and 6.8% experienced disease relapse after complete response (CR) to initial therapy.⁴⁶

Rituximab, a CD20-directed monoclonal antibody with indications in certain adults with NHL,⁴⁷ may be included for low-risk Group B patients (see "Group B," page 1113), and is recommended for patients with high-risk Group B and Group C disease.

Group A

Group A patients should receive the POG9219 regimen or the FAB/LMB96 regimen A if they are not enrolled in a clinical trial, with the exception of Group A patients with any detectable bone marrow disease, who should be treated as Group B.

The POG9219 regimen is based on 2 trials with a total of 340 pediatric patients with stage I or II NHL, resected or not (ie, Group A and low-risk Group B), conducted by the POG between 1983 and 1991.⁴⁸ In the first trial, patients were randomized to receive induction and consolidation chemotherapy with or without radiation therapy (RT). In the second trial, all patients received

^mSee Principles of Supportive Care (PBCL-D*).

ⁿThe BFM has equivalent regimens that are not standardly used in North America.

^oRadiation therapy rarely has a role in pediatric aggressive mature B-cell lymphomas due to the rapid lysis of tumor to chemotherapy and the avoidance of long-term side effects in children.

^pSee Principles of Systemic Therapy (PBCL-B*).

^xFDG-PET/CT or FDG-PET/MRI may be considered, if not obtained as part of diagnostic evaluation. FDG-PET should not replace imaging with contrast-enhanced diagnostic quality CT or MRI. A patient's therapy should not be escalated based on FDG-PET alone. If a residual lesion is FDG-PET negative (Deauville 1, 2 or 3; See PBCL-C 2 of 2), biopsy is not necessary. In the absence of clinical concern, FDG-PET does not need to be repeated once it is negative. False negatives are unusual. False positives are common.

^ySee Response Criteria (PBCL-C).

^zResidual mass should be biopsied prior to categorizing it as residual disease.

^{hh}Reassess sites of original disease with radiologic studies as indicated (abdominal ultrasound, chest/abdominal/pelvic CT with contrast, and/or MRI of the head, neck, abdomen, and/or pelvis). Bone marrow and CSF studies should also be performed if bone marrow or CSF were initially involved.

ⁱⁱCOG protocol ANHL1131 distinguished between lymphomatous CNS or parameningeal disease (CNS+) and lymphoma cells in the CSF (CSF+). CSF+ patients were treated on arm C3. The relative efficacy of the arm C1 and arm C3 regimens has not been evaluated. Therefore, either regimen is an acceptable choice for treatment of CSF+ patients.

^{jj}For patients on regimen C1 therapy with less than 20% response to the reduction phase, continue regimen C1 therapy or change to regimen C3 therapy.

*Available in the supplemental online content at JNCCN.org.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-8

induction and consolidation chemotherapy without RT, and those with complete remission after 9 weeks were randomized to continuation of therapy or no continuation. The chemotherapy regimen included vincristine, doxorubicin, cyclophosphamide, and prednisone. The 5-year rates of continuous complete remission were 89%, 86%, and 88%, respectively, for those who received 9 weeks of chemotherapy without RT, 8 months of chemotherapy without RT, and 8 months of chemotherapy with RT. These results indicate that 9 weeks of chemotherapy is sufficient in this group of patients.

The FAB/LMB96 international study included pediatric patients with all stages of NHL.⁴⁹ All patients with resected stage I or completely resected abdominal stage II disease received 2 courses of COPAD (cyclophosphamide, vincristine, prednisone, and doxorubicin) without intrathecal therapy after surgery (Regimen A). After a median follow-up of 50.5 months, the 4-year event-free survival (EFS; with events defined as treatment failure for any reason) was 98.3% and overall survival (OS) was 99.2%.

Alternatively, an equivalent BFM regimen can be considered. The NHL-BFM95 trial was a randomized

noninferiority study that compared methotrexate infused over 4 hours with a 24-hour infusion in patients with stage I or II B-cell NHL in an attempt to reduce toxicity.⁵⁰ Patients in Group A received 2 cycles of chemotherapy; failure-free survival at 1 year in this group was 95% ± 5% (n=20) versus 100% (n=19) for the 4-hour and 24-hours arms, respectively, meeting the noninferiority endpoint. The incidence of grade 3/4 mucositis was significantly lower in the 4-hour arm in all risk groups.

Group B

Low-risk Group B patients with stage I or II disease can be treated with the POG9219 regimen as for patients with Group A disease (discussed previously), or with the COG ANHL1131 regimen B with or without rituximab. The latter regimen is the only recommended option for low-risk Group B patients with stage III disease and normal LDH levels (with or without rituximab) and for patients with high-risk Group B disease (with rituximab). Rituximab has not been tested in clinical trials for patients with low-risk Group B. However, in keeping with adult practice and data on efficacy and toxicity in

DISEASE SURVEILLANCE/FOLLOW-UP

- H&P
 - Burkitt lymphoma
 - ◊ Every month for one year
 - ◊ Then every 3 months for year 2
 - ◊ Then every 6 months for year 3
 - ◊ Then annually
 - Diffuse large B-cell lymphoma
 - ◊ Every 3 months for 3 years
 - ◊ Then annually
- CBC with differential
 - Monthly until counts are normal then at each exam visit
- Ultrasound of abdominal tumors
 - 3 months after therapy, if clinical concern
- Routine surveillance imaging is not recommended. Consider FDG-PET/CT or FDG-PET/MRI or chest/abdominal/pelvic CT with contrast only if clinical suspicion of relapse

→ Relapse^{kk} → See Therapy for Relapsed or Refractory Disease (PBCL-10)

LATE EFFECTS MONITORING

- Attention to cardiac, gonadal, and neurocognitive function, bone health, and risk of secondary leukemia. (See Children's Oncology Group Survivorship Guidelines)

^{kk}Pathologic confirmation of relapse is recommended before starting relapse therapy, and restaging workup should be completed as for initial diagnosis.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-9

high-risk patients (see following paragraphs), the panel deems the inclusion of rituximab in the treatment of this patient population to be appropriate.

COG ANHL1131 regimen B is based on that used for Group B patients in the FAB/LMB96 trial.⁵¹ In that trial, patients with Group B disease received COP reduction, followed by induction with two courses of COPADM with either full-dose or half-dose cyclophosphamide for those with good response, followed by consolidation with two courses of CYM, and then followed by maintenance or no maintenance for those with continued response. Intrathecal therapy was included. The results showed that treatment reductions did not have significant effects on EFS. Therefore, COG ANHL1131, a trial comparing EFS in pediatric patients with high-risk Group B or Group C NHL treated with and without rituximab, used the lower-intensity chemotherapy as its backbone.⁵²

The use of rituximab in high-risk Group B patients is supported by the COG ANHL01P1 trial.⁵³ In this international study of patients <30 years of age with high-risk (stage III/IV) Group B mature B-cell lymphoma, 45 patients received FAB/LMB96 chemotherapy plus rituximab. No serious adverse events were attributed to rituximab, and

3-year EFS was 93% (95% CI, 79%–98%). Likewise, initial results of the COG ANHL1131 trial support the improved efficacy of rituximab in addition to standard LMB therapy in children and adolescents with high-risk BL and DLBCL.⁵⁴ This trial, which randomized 310 patients with high-risk mature B-cell lymphomas between standard LMB chemotherapy and the same chemotherapy with the addition of rituximab, demonstrated a 1-year EFS of 95% in the rituximab group versus 81.5% in the chemotherapy only group, a statistically significant difference.

The panel recommends COG ANHL1131 regimen B starting with a COP reduction phase with or without rituximab for patients in low-risk Group B and with rituximab for those in high-risk Group B. Those with <20% tumor reduction after COP start induction with R-COPADM1 of COG ANHL1131 regimen C1 CNS-negative with rituximab, even if rituximab was not included initially (see “Group C,” next page). Those with ≥20% tumor reduction after COP reduction proceed to COPADM1 induction of COG ANHL1131 regimen B with or without rituximab, based on initial therapy (ie, if rituximab was included at day 6 of COP reduction, it should be continued throughout therapy). A second

**THERAPY FOR RELAPSE OR
REFRACTORY DISEASE^{m,II}**

Clinical trial (preferred)
or
R-CYVE^V if not previously
received as part of initial therapy
or
RICE^V

Response
assessment^{x,hh}

RESPONSE^y

CR^{mm}

PR

<PR

CONSOLIDATION/ADDITIONAL THERAPY^{m,nn}

Autologous hematopoietic stem cell transplant (HSCT)^{oo} or
Allogeneic HSCT from best available donor^{oo}
• Human leukocyte antigen [HLA]-matched related donor
• HLA-matched unrelated donor
• Cord blood
• Haploidentical donor

Clinical trial^{pp}
or
Autologous HSCT or allogeneic HSCT^{oo}
or
Best supportive care

Clinical trial^{pp}
or
Best supportive care

^mSee Principles of Supportive Care (PBCL-D*).

^VSee Principles of Systemic Therapy (PBCL-B*).

^xFDG-PET/CT or FDG-PET/MRI may be considered, if not obtained as part of diagnostic evaluation. FDG-PET should not replace imaging with contrast-enhanced diagnostic quality CT or MRI. A patient's therapy should not be escalated based on FDG-PET alone. If a residual lesion is FDG-PET negative (Deauville 1, 2 or 3; See PBCL-C 2 of 2), biopsy is not necessary. In the absence of clinical concern, FDG-PET does not need to be repeated once it is negative. False negatives are unusual. False positives are common.

^{hh}See Response Criteria (PBCL-C).

^{hh}Reassess sites of original disease with radiologic studies as indicated (abdominal ultrasound, chest/abdominal/pelvic CT with contrast, and/or MRI of the head, neck, abdomen, and/or pelvis). Bone marrow and CSF studies should also be performed if bone marrow or CSF were initially involved.

^{II}It is rare for patients who are risk group A at initial diagnosis to relapse. There are little data and no proven standard of care for these patients, and transplant is usually not considered. For patients with a low risk of relapse (defined as patients with initial Group A disease or patients with low stage [Stage I or II] Group B treated along POG9219), chemotherapy regimens such as COG ANHL 1131 (Arm C1 regimen) or 2 cycles of R-CYVE without consolidative transplant are options that can be considered.

[†]To view the most recent version of these guidelines, visit NCCN.org.

*Available in the supplemental online content at JNCCN.org.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

^{mm}Patients with late relapse from early-stage disease after a complete response to relapse-refractory therapy may not require consolidation with transplant.

ⁿⁿFor conditioning therapy used in transplant, institutions can use their center's choice of myeloablative regimen. Retrospective studies showed efficacy of many regimens (eg, busulfan-cyclophosphamide-etoposide, BEAM [carmustine-etoposide-cytarabine-melphalan], CBV^{low} [low-dose cyclophosphamide-carmustine-etoposide]).

^{oo}There are no data to support autologous versus allogeneic HSCT; therefore, the decision regarding transplant should be based on physician preference.

^{pp}Second-line therapy for relapsed/refractory disease should be in a clinical trial with incorporation of investigational agent). Regimens and agents used for adults with relapsed/refractory DLBCL can also be considered. See BCEL-C 2 of 4 from the NCCN Guidelines for B-Cell Lymphomas[†].

PBCL-10

response assessment is performed in these initial responders after consolidation 1. Those with CR continue regimen B with or without rituximab based on initial therapy, while those with a less than CR change to COG ANHL1131 regimen C1 CNS-negative with rituximab, starting with R-CYVE1 (see "Group C," below).

Alternatively, an equivalent BFM regimen can be used. In the NHL-BFM95 trial (see "Group A," page 1112), patients with nonresected stage I or stage II disease and those with stage III disease and LDH <500 U/L received 5 cycles of therapy, including a cytoreductive prephase.⁵⁰ Failure-free survival at 1 year for the 4-hour versus the 24-hour infusion was 94% ± 2% versus 96% ± 2% in these patients. The NHL-BFM90 trial included a cytoreductive prephase, followed by 6 courses of chemotherapy with intrathecal therapy for patients with high-risk Group B and Group C disease.⁵⁵ The 6-year pEFS was 78% ± 3% in this group of patients.

Group C

The recommended treatment regimens for patients in Group C are those being used in COG ANHL1131 (see previous sections) and are dependent on CNS

and CSF involvement.⁵² These regimens are based on those used in the FAB/LMB96 trial, with omission of 2 maintenance cycles.^{45,51} The COG ANHL1131 Arm C1 CNS-positive regimen is an option for patients with CNS-positive disease, regardless of CSF positivity. Patients with CNS and CSF involvement can alternatively be treated according to the Arm C3 regimen. The relative efficacy of the C3 versus the C1 regimen for CSF-positive patients has not been established. Patients without CNS involvement should receive the Arm C1 CNS-negative regimen.

Rituximab should be included for all patients in Group C. The small COG ANHL01P1 study in pediatric patients with CNS and/or bone marrow-positive BL evaluated FAB/LMB96 chemotherapy with rituximab.⁵⁶ The 3-year EFS/OS was 90% (95% CI, 76%–96%) in the 40 evaluable patients, and the regimen was well tolerated. In addition, a combined analysis of results from the inclusion of rituximab for patients with CNS involvement in the FAB/LMB96 C1 arm and COG ANHL01P1 showed that EFS and OS were improved with rituximab compared with historic LMB89 results.⁵⁷ Other studies have also seen high cure rates with the use of rituximab in these patients.^{58,59} The randomized comparison of

RESPONSE CRITERIA

Table 1: International Pediatric Non-Hodgkin Lymphoma Response Criteria ^a	
Criterion	Definition
CR	Disappearance of all disease
CR	<ul style="list-style-type: none"> CT or MRI reveals no residual and no new lesions Residual mass pathologically negative for disease BM and CSF free of disease pathologically
CRb	<ul style="list-style-type: none"> Residual mass with no pathologic evidence of disease from limited or core biopsy; no new lesions by imaging examination BM and CSF free of disease pathologically No new and/or progressive disease elsewhere
CRu	<ul style="list-style-type: none"> Residual mass negative by FDG-PET; no new lesions by imaging examination BM and CSF free of disease pathologically No new and/or progressive disease elsewhere
PR	<ul style="list-style-type: none"> ≥50% decrease in SPD on CT or MRI; FDG-PET may be positive (Deauville score 4 or 5 with reduced lesional uptake compared to baseline [See Table 2]). May have evidence of disease in BM or CSF if present at diagnosis, but should have 50% reduction in percentage of lymphoma cells. No new and/or progressive disease
MR	<ul style="list-style-type: none"> Decrease in SPD >25%, but <50% on CT or MRI May have evidence of disease in BM or CSF if present at diagnosis, but should have 25% to 50% reduction in percentage of lymphoma cells No new and/or progressive disease
NR	Not meeting CR, PR, MR, or PD criteria
PD	<ul style="list-style-type: none"> >25% increase in SPD on CT or MRI; Deauville score 4 or 5 [See Table 2] on FDG-PET with increase in lesional uptake from baseline; or new morphologic disease in BM or CSF

Abbreviations	
BM	Bone marrow
CR	Complete response
CRb	Complete response biopsy negative
CRu	Complete response unconfirmed
MR	Minor response
NR	No response
PD	Progressive disease
PR	Partial response
SPD	Sum of product of greatest perpendicular diameters

^aAdapted with permission from Sandlund JT, Guillermin RP et al. International Pediatric Non-Hodgkin Lymphoma Response Criteria. J Clin Oncol 2015; 33(18):2106-2111.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

PBCL-C
1 OF 2

chemotherapy with and without rituximab in the COG ANHL1131 has been published only in abstract form to date.⁵²

An equivalent BFM regimen can be used for patients in Group C. In the NHL-BFM90 and NHL-BFM95 trials, Group C patients received a cytoreductive prephase and 6 courses of chemotherapy.^{50,55}

Response Assessment

Response assessment is critical during therapy for patients with pediatric aggressive mature B-cell lymphomas, especially for Group B patients on COG ANHL1131 regimen B, because their treatment depends on the level of response to early rounds of therapy.

Sites of original disease should be reassessed with radiologic studies as indicated (abdominal ultrasound, chest/abdominal/pelvic CT with contrast, and/or MRI of the head, neck, abdomen, and/or pelvis). Bone marrow and CSF studies should also be performed if they were initially involved.

FDG-PET/CT or FDG-PET/MRI may be considered if not obtained as part of diagnostic evaluation. FDG-PET should not replace imaging with contrast-enhanced

diagnostic-quality CT or MRI. A patient's therapy should not be escalated based on FDG-PET alone. If a residual lesion is FDG-PET negative (Deauville 1, 2, or 3⁶⁰), biopsy is not necessary because of the high negative predictive value of FDG-PET.^{61–65} In the absence of clinical concern, FDG-PET does not need to be repeated once it is negative. It is important to note, however, that the positive predictive value of FDG-PET is fairly low.⁶⁶ False-positive findings may include inflammation, necrotic tumor, reactive lymphadenitis, brown fat, thymic rebound, and secondary malignancy.

The panel recommends use of the International Pediatric NHL Response Criteria, as adapted in these guidelines.⁶⁷ In the response criteria system, disease is classified as progressive disease, no response, minimal response, partial response, and CR. For patients with less than CR by these criteria at the end of therapy, the residual mass should be biopsied to confirm the presence or absence of residual disease. The majority of residual masses at the end of therapy are necrotic tumor.

Surveillance

As few as 5% of patients treated for BL or DLBCL experience a relapse.^{68,69} Most of these relapses occur in

RESPONSE CRITERIA

Table 2: The Deauville Five-Point Scale ^b	
Score	Definition
1	No uptake
2	Uptake ≤ mediastinum
3	Uptake > mediastinum but ≤ liver
4	Uptake moderately > liver
5	Markedly increased uptake at any site or new lesions
X	New areas of uptake unlikely to be due to lymphoma

^bAdapted with permission from Meignan M, Gallamini A, Meignan M, et al. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009 Aug;50(8):1257-1260.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

the first 6 months after treatment, with fewer than 10% of relapses occurring after 15 months.^{68,69} DLBCL relapses tend to occur later than BL relapses and may be seen up to 3 years after treatment. Treatment of relapsed disease can lead to sustained complete second remissions in some patients.^{68–73} Therefore, patients with a CR to initial treatment should undergo routine clinical surveillance.

A history and physical exam is recommended more frequently in the first 3 years, and then annually. A CBC with differential is recommended monthly until counts are normal, and then at each exam visit. Routine surveillance imaging is not recommended. FDG-PET/CT or FDG-PET/MRI and chest/abdominal/pelvic CT with contrast should only be considered if there is a clinical suspicion of relapse.⁷⁴ Ultrasound of abdominal tumors is indicated 3 months after therapy if there is clinical concern.

In addition, patients should be monitored for late effects of treatment as per the COG Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers (available at www.survivorshipguidelines.org). In particular, attention should be paid

to cardiac, gonadal, and neurocognitive function; bone health; and the risk for secondary leukemia.

Subsequent Therapy for Relapsed or Refractory Disease

Treatment of patients with relapsed or refractory disease is systemic therapy, with clinical trial participation preferred. Systemic therapy options for most patients are *R*-CYVE (if not previously received as part of initial therapy) or *R*-ICE. Consolidation therapy is recommended based on response (see later sections).

It is rare for patients who had Group A disease at initial diagnosis to relapse, and there are little data and no proven standard of care for these patients. For patients with a low risk of relapse (defined as patients with initial Group A disease or patients with low stage [stage I or II] Group B treated according to POG9219), chemotherapy regimens such as COG ANHL 1131 (arm C1 regimen) or 2 cycles of *R*-CYVE without consolidative transplant are options that can be considered.

CYVE and ICE were used in the relapse/refractory setting in the LMB89, LBM96, and LBM2001 studies with 29.9% 5-year survival rate for patients with relapses.⁶⁸

STAGING

International Pediatric Non-Hodgkin Lymphoma Staging System ^{a,b}	
Stage I	A single tumor not in the mediastinum and abdomen
Stage II	<ul style="list-style-type: none"> • A single extranodal tumor with regional node involvement • Two or more nodal areas on the same side of the diaphragm • A primary gastrointestinal tract tumor (usually in the ileocecal area), with or without involvement of associated mesenteric nodes, that is completely resectable (if ascites or extension of the tumor to adjacent organs, it should be regarded as stage III)
Stage III	<ul style="list-style-type: none"> • Two or more extranodal tumors (including bone or skin) • Two or more nodal areas above and below the diaphragm • Any intrathoracic tumor (mediastinal, hilar, pulmonary, pleural, or thymic) • Intra-abdominal and retroperitoneal disease, including liver, spleen, ovary, and/or kidney localizations, regardless of degree of resection • Any paraspinous or epidural tumor, whether or not other sites are involved • Single bone lesion with concomitant involvement of extra-nodal and/or non-regional nodal sites.
Stage IV	Any of the above findings with initial involvement of the CNS, ^c bone marrow, ^d or both.

^aAdapted with permission from Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol 2015;33(18):2112-2118.

^bThis is a revised version of the Murphy's St. Jude Staging from Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-339.

^cCNS is considered involved if one or more of the following apply:

- Any lymphoma cells by cytology in CSF
- Any CNS tumor mass by imaging
- Cranial nerve palsy (if not explained by extracranial tumor)
- Clinical spinal cord compression
- Parameningeal extension: cranial and/or spinal

^dStage IV disease, due to bone marrow involvement, is defined by morphologic evidence of any lymphoma cells in a bone marrow aspirate.

Version 2.2020, 04/10/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

ST-1

After 1996, 16 relapsed/refractory patients received rituximab with CYVE or ICE. Six patients were in complete remission after relapse/refractory treatment, but there was no difference in survival rates between those that did and did not receive rituximab.^{68,69} A multicenter case series in the United Kingdom, however, demonstrated an association between rituximab and survival in the relapse/refractory setting.⁷⁵ In a small COG study, patients with relapsed/refractory NHL received rituximab with ICE (ie, R-ICE).⁷⁶ Toxicities were manageable. The CR/PR rate was 60% in 20 evaluable patients, with 30% able to complete consolidation therapy. In addition, a Japanese study reported a 73% response rate from 223 patients treated with R-ICE in this setting.⁷⁷

Consolidation Therapy

Most patients with relapsed/refractory disease with a CR to systemic therapy should receive an autologous or allogeneic hematopoietic stem cell transplant (HSCT). The exception is for patients with Group A or stage I/II Group B disease at diagnosis (see "Subsequent Therapy for Relapsed or Refractory Disease," page 1117). In the multicenter case series in the United Kingdom

mentioned previously, 9 of 16 patients who received HSCT survived >6 years; no patient who did not receive transplant survived.⁷⁵ In another case series, OS was better for patients who received transplant compared with patients who did not ($P<.01$).⁷¹ Other studies have also shown comparable survival rates for patients who undergo HSCT in this setting.^{70,73,78,79}

No data support autologous versus allogeneic HSCT; therefore, the decision regarding type of transplant should be based on physician preference.^{78,80} For an allogeneic transplant, the best available donor should be used: generally, a human leukocyte antigen–matched related donor is the best option, followed by a human leukocyte antigen–matched unrelated donor, then cord blood or a haploidentical donor.^{81,82}

Patients with a partial response to initial therapy for relapsed/refractory disease can also receive an autologous or allogeneic HSCT. For patients with partial response or less than a partial response, a clinical trial of second-line systemic therapy with incorporation of investigational agents can be considered, as can regimens and agents used for adults with relapsed/refractory DLBCL. Best supportive care is another option.

Supportive Care

Supportive care issues that are important in pediatric patients with cancer during treatment include management of pain, chemotherapy-induced nausea and vomiting, fatigue, anxiety and depression, fever and neutropenia, neurologic complications, dermatitis, and mucositis.^{83–86} The COG and others have evidence-based guidelines addressing some of these supportive care issues, as well as guidelines on antifungal prophylaxis, fertility preservation, and platelet transfusion.^{87–92} In addition, parents and other caregivers of children with cancer frequently experience distress, depression, and even symptoms of posttraumatic stress disorder due to the stress of watching a child suffering and endangered and the increased financial burden due to medical costs and disruptions in employment.^{84,93–95}

Specific to the treatment regimens recommended for pediatric patients with BL or DLBCL, there is a high risk of serious infections associated with profound neutropenia and severe mucosal toxicity.⁹⁶ Rituximab is associated with hepatitis B reactivation, and hepatitis B virus polymerase chain reaction monitoring and antiviral prophylaxis is recommended for HBsAg-positive patients.⁹⁷ The “Principles of Supportive Care” in the algorithm (see supplemental online content at JNCCN.org) list other recommendations for infection prophylaxis and treatment of these patients.

Organ dysfunction and tumor mass effects can affect pediatric patients with BL and DLBCL, causing significant

morbidity. Spinal cord compression, kidney injury and obstructive uropathy, intussusception, bowel obstruction, chest masses with risk of superior vena cava syndrome, and hepatopathy have been described.^{98,99} Chemotherapy should be started as soon as possible to preserve organ function and reduce complications for these patients.

Tumor Lysis Syndrome

One of the most critical supportive care needs of pediatric patients with BL and DLBCL is the prevention and management of tumor lysis syndrome (TLS). TLS results from spontaneous or therapy-induced rapid tumor necrosis and release of tumor cell contents into the blood stream.^{100,101} It can be asymptomatic or can cause major metabolic derangements leading to seizures, cardiac arrhythmias, acute renal failure, neuromuscular abnormalities, hypotension, and death. Risk factors include bulky disease at presentation, elevated LDH, oliguria, preexisting renal impairment, dehydration, and evidence of TLS before start of therapy.

Prophylaxis with allopurinol or rasburicase before start of systemic therapy is indicated for certain patients as described in the “Principles of Supportive Care” in the algorithm (see supplemental online content at JNCCN.org).¹⁰² Management of hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia associated with TLS is also described in that section of the algorithm.^{100,101,103,104}

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7–30. <https://www.ncbi.nlm.nih.gov/pubmed/31912902>
2. Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. *Hematology (Am Soc Hematol Educ Program)* 2016;2016:589–597. <https://www.ncbi.nlm.nih.gov/pubmed/27913533>
3. Casulo C, Friedberg JW. Burkitt lymphoma- a rare but challenging lymphoma. *Best Pract Res Clin Haematol* 2018;31:279–284. <https://www.ncbi.nlm.nih.gov/pubmed/30213397>
4. Moormann AM, Snider CJ, Chelimo K. The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma. *Curr Opin Infect Dis* 2011;24:435–441. <https://www.ncbi.nlm.nih.gov/pubmed/21885920>
5. Gouveia MH, Bergen AW, Borda V, et al. Genetic signatures of gene flow and malaria-driven natural selection in sub-Saharan populations of the “endemic Burkitt Lymphoma belt”. *PLoS Genet* 2019;15:e1008027. <https://www.ncbi.nlm.nih.gov/pubmed/30849090>
6. Parkin DM, Sitas F, Chirenje M, et al. Part I: Cancer in Indigenous Africans—burden, distribution, and trends. *Lancet Oncol* 2008;9: 683–692. <https://www.ncbi.nlm.nih.gov/pubmed/18598933>
7. Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. *Blood* 2018;131:2670–2681. <https://www.ncbi.nlm.nih.gov/pubmed/29545328>
8. Högfeldt T, Jaing C, Loughlin KM, et al. Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions. *Oncol Lett* 2016;12:2782–2788. <https://www.ncbi.nlm.nih.gov/pubmed/27698858>
9. Nomura Y, Lavu EK, Muta K, et al. Histological characteristics of 21 Papua New Guinean children with high-grade B-cell lymphoma, which is frequently associated with EBV infection. *Pathol Int* 2008;58:695–700. <https://www.ncbi.nlm.nih.gov/pubmed/18844934>
10. U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: http://www.nlm.nih.gov/bsd/bsd_key.html. Accessed November 14, 2019.
11. Chung EM, Pavia M. Pediatric extranodal lymphoma. *Radiol Clin North Am* 2016;54:727–746. <https://www.ncbi.nlm.nih.gov/pubmed/27265605>
12. Miron I, Miron L, Lupu VV, et al. Silent presentation of multiple metastasis Burkitt lymphoma in a child: a case report and review of the literature. *Medicine (Baltimore)* 2017;96:e7518. <https://www.ncbi.nlm.nih.gov/pubmed/28700504>
13. Iyer VK. Pediatric lymphoma diagnosis: role of FNAC, biopsy, immunohistochemistry and molecular diagnostics. *Indian J Pediatr* 2013; 80:756–763. <https://www.ncbi.nlm.nih.gov/pubmed/23925793>
14. Swerdlow SH, Campo E, Harris NL, et al., eds. Burkitt Lymphoma. In: *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, Vol. 2. Lyon, France: IARC;2017.
15. Swerdlow SH, Campo E, Harris NL, et al., eds. Diffuse Large B-Cell Lymphoma, NOS. In: *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, Vol. 2. Lyon, France: IARC;2017.
16. Huang H, Liu ZL, Zeng H, et al. Clinicopathological study of sporadic Burkitt lymphoma in children. *Chin Med J (Engl)* 2015;128:510–514. <https://www.ncbi.nlm.nih.gov/pubmed/25673455>
17. Boerma EG, Siebert R, Kluin PM, et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. *Leukemia* 2009;23: 225–234. <https://www.ncbi.nlm.nih.gov/pubmed/18923440>
18. Maria Murga Penas E, Schilling G, Behrmann P, et al. Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic

- evolution, and comparison with primary samples. *Genes Chromosomes Cancer* 2014;53:497–515. <https://www.ncbi.nlm.nih.gov/pubmed/24590883>
19. Scholtysik R, Kreuz M, Klapper W, et al. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. *Haematologica* 2010;95:2047–2055. <https://www.ncbi.nlm.nih.gov/pubmed/20823134>
 20. Toujani S, Dessen P, Ithzar N, et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. *PLoS One* 2009;4:e7089. <https://www.ncbi.nlm.nih.gov/pubmed/19759907>
 21. Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. *Cancer* 2012;118:4173–4183. <https://www.ncbi.nlm.nih.gov/pubmed/22213394>
 22. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. *J Clin Oncol* 2010;28:3360–3365. <https://www.ncbi.nlm.nih.gov/pubmed/20498406>
 23. Clipson A, Barrans S, Zeng N, et al. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. *J Pathol Clin Res* 2015;1:125–133. <https://www.ncbi.nlm.nih.gov/pubmed/27347428>
 24. Szczepanowski M, Lange J, Kohler CW, et al. Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents. *Br J Haematol* 2017;179:116–119. <https://www.ncbi.nlm.nih.gov/pubmed/28643426>
 25. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. *Blood* 2009;114:2273–2279. <https://www.ncbi.nlm.nih.gov/pubmed/19597184>
 26. Lu B, Zhou C, Yang W, et al. Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients. *Leuk Lymphoma* 2011;52:2356–2364. <https://www.ncbi.nlm.nih.gov/pubmed/21740296>
 27. Perry AM, Crockett D, Dave BJ, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: study of 39 cases. *Br J Haematol* 2013;162:40–49. <https://www.ncbi.nlm.nih.gov/pubmed/23600716>
 28. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. *Am J Surg Pathol* 2010;34:327–340. <https://www.ncbi.nlm.nih.gov/pubmed/20118770>
 29. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. *Haematologica* 2009;94:935–943. <https://www.ncbi.nlm.nih.gov/pubmed/19535347>
 30. Nicolae A, Pittaluga S, Abdullah S, et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. *Blood* 2015;126:863–872. <https://www.ncbi.nlm.nih.gov/pubmed/25999451>
 31. Vaillant V, Reiter A, Zimmermann M, et al. Seroepidemiological analysis and literature review of the prevalence of Epstein-Barr virus and herpesvirus infections in pediatric cases with non-Hodgkin lymphoma in Central Europe. *Pediatr Blood Cancer* 2019;66:e27752. <https://www.ncbi.nlm.nih.gov/pubmed/30977593>
 32. Satou A, Asano N, Nakazawa A, et al. Epstein-Barr virus (EBV)-positive sporadic burkitt lymphoma: an age-related lymphoproliferative disorder? *Am J Surg Pathol* 2015;39:227–235. <https://www.ncbi.nlm.nih.gov/pubmed/25321330>
 33. Aukema SM, Theil L, Rohde M, et al. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. *Br J Haematol* 2015;170:814–825. <https://www.ncbi.nlm.nih.gov/pubmed/26104998>
 34. Pienkowska-Grela B, Rymkiewicz G, Grygalewicz B, et al. Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement. *Med Oncol* 2011;28:1589–1595. <https://www.ncbi.nlm.nih.gov/pubmed/20661666>
 35. Wagener R, Seufert J, Raimondi F, et al. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. *Blood* 2019;133:962–966. <https://www.ncbi.nlm.nih.gov/pubmed/30567752>
 36. Yanik EL, Shiels MS, Smith JM, et al. Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States. *Cancer* 2017;123:4663–4671. <https://www.ncbi.nlm.nih.gov/pubmed/28759103>
 37. Lones MA, Sanger WG, Le Beau MM, et al. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08. *J Pediatr Hematol Oncol* 2004;26:169–178. <https://www.ncbi.nlm.nih.gov/pubmed/15125609>
 38. Hutchison RE, Finch C, Kepner J, et al. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons. *Ann Oncol* 2000;11(Suppl 1):S35–38. <https://www.ncbi.nlm.nih.gov/pubmed/10707776>
 39. Cairo MS, Spoto R, Perkins SL, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. *Br J Haematol* 2003;120:660–670. <https://www.ncbi.nlm.nih.gov/pubmed/12588354>
 40. Riad R, Omar W, Kotb M, et al. Role of PET/CT in malignant pediatric lymphoma. *Eur J Nucl Med Mol Imaging* 2010;37:319–329. <https://www.ncbi.nlm.nih.gov/pubmed/19756591>
 41. Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. *J Clin Oncol* 2007;25:3915–3922. <https://www.ncbi.nlm.nih.gov/pubmed/17761975>
 42. Cairo MS, Spoto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. *J Clin Oncol* 2012;30:387–393. <https://www.ncbi.nlm.nih.gov/pubmed/22215753>
 43. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. *Semin Oncol* 1980;7:332–339. <https://www.ncbi.nlm.nih.gov/pubmed/7414342>
 44. Rosolen A, Perkins SL, Pinkerton CR, et al. Revised international pediatric non-Hodgkin lymphoma staging system. *J Clin Oncol* 2015;33:2112–2118. <https://www.ncbi.nlm.nih.gov/pubmed/25940716>
 45. Cairo MS, Gerrard M, Spoto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. *Blood* 2007;109:2736–2743. <https://www.ncbi.nlm.nih.gov/pubmed/17138821>
 46. Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. *Br J Haematol* 2018;182:859–869. <https://www.ncbi.nlm.nih.gov/pubmed/29984828>
 47. Genentech, Inc. RITUXAN® (rituximab) injection, for intravenous use. 2019. Accessed November 14, 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103705s54571bl.pdf
 48. Link MP, Shuster JJ, Donaldson SS, et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. *N Engl J Med* 1997;337:1259–1266. <https://www.ncbi.nlm.nih.gov/pubmed/9345074>
 49. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. *Br J Haematol* 2008;141:840–847. <https://www.ncbi.nlm.nih.gov/pubmed/18371107>
 50. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. *Blood* 2005;105:948–958. <https://www.ncbi.nlm.nih.gov/pubmed/15486066>
 51. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. *Blood* 2007;109:2773–2780. <https://www.ncbi.nlm.nih.gov/pubmed/17132719>
 52. Intergroup randomized trial for children or adolescents with B-cell non Hodgkin lymphoma or B-acute leukemia: Rituximab evaluation in high risk patients. Gustave Roussy, Cancer Campus, Grand Paris; Children's Oncology Group; 2017. Accessed May 24, 2019. Available at: <https://clinicaltrials.gov/ct2/show/NCT01516580>

53. Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. *Leukemia* 2013;27:1174–1177. <https://www.ncbi.nlm.nih.gov/pubmed/22940833>
54. Minard-Colin V, Auperin A, Pilon M, et al. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen [abstract]. *J Clin Oncol* 2016;34.15_suppl:10507. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.10507.
55. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. *Blood* 1999;94:3294–3306. <https://www.ncbi.nlm.nih.gov/pubmed/10552938>
56. Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. *Br J Haematol* 2014;167:394–401. <https://www.ncbi.nlm.nih.gov/pubmed/25066629>
57. Frazer JK, Li KJ, Galardy PJ, et al. Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemioimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. *Br J Haematol* 2019;185:374–377. <https://www.ncbi.nlm.nih.gov/pubmed/30117142>
58. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. *J Clin Oncol* 2010;28:3115–3121. <https://www.ncbi.nlm.nih.gov/pubmed/20516455>
59. Samochatova EV, Maschan AA, Shelikhova LN, et al. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. *J Pediatr Hematol Oncol* 2014;36:395–401. <https://www.ncbi.nlm.nih.gov/pubmed/23823112>
60. Meignan M, Gallamini A, Meignan M, et al. Report on the first international workshop on interim-PET-scan in lymphoma. *Leuk Lymphoma* 2009;50:1257–1260. <https://www.ncbi.nlm.nih.gov/pubmed/19544140>
61. Bailly C, Eugène T, Couec ML, et al. Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. *Front Med (Lausanne)* 2014;1:54. <https://www.ncbi.nlm.nih.gov/pubmed/25593926>
62. Abdel Rahman H, Sedky M, Hamada A, et al. Role of FDG-PET scan in the management of pediatric mature B cell non-Hodgkin's lymphoma. CCHE experience. *J Egypt Natl Canc Inst* 2016;28:95–99. <https://www.ncbi.nlm.nih.gov/pubmed/27133974>
63. Bhojwani D, McCarville MB, Choi JK, et al. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. *Br J Haematol* 2015;168:845–853. <https://www.ncbi.nlm.nih.gov/pubmed/25382494>
64. Furth C, Erdreich AS, Steffen IG, et al. Interim PET response criteria in paediatric non-Hodgkin's lymphoma. Results from a retrospective multicenter reading. *Nucl Med (Stuttg)* 2013;52:148–156. <https://www.ncbi.nlm.nih.gov/pubmed/23928982>
65. Karantanis D, Durski JM, Lowe VJ, et al. 18F-FDG PET and PET/CT in Burkitt's lymphoma. *Eur J Radiol* 2010;75:e68–e73. <https://www.ncbi.nlm.nih.gov/pubmed/19716248>
66. Riad R, Omar W, Sidhom I, et al. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma. *Nucl Med Commun* 2010;31:232–238. <https://www.ncbi.nlm.nih.gov/pubmed/20032800>
67. Sandlund JT, Guillermin RP, Perkins SL, et al. International pediatric non-Hodgkin lymphoma response criteria. *J Clin Oncol* 2015;33:2106–2111. <https://www.ncbi.nlm.nih.gov/pubmed/25940725>
68. Jourdain A, Auperin A, Minard-Colin V, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study. *Haematologica* 2015;100:810–817. <https://www.ncbi.nlm.nih.gov/pubmed/25724577>
69. Rigaud C, Auperin A, Jourdain A, et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. *Pediatr Blood Cancer* 2019;66:e27873. <https://www.ncbi.nlm.nih.gov/pubmed/31207026>
70. Fujita N, Mori T, Mitsui T, et al. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. *Pediatr Blood Cancer* 2008;51:188–192. <https://www.ncbi.nlm.nih.gov/pubmed/18428432>
71. Kim H, Park ES, Lee SH, et al. Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. *Cancer Res Treat* 2014;46:358–365. <https://www.ncbi.nlm.nih.gov/pubmed/25043820>
72. Hartmann O, Pein F, Beaujean F, et al. High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. *J Clin Oncol* 1984;2:979–985. <https://www.ncbi.nlm.nih.gov/pubmed/6381657>
73. Naik S, Martinez CA, Omer B, et al. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. *Blood Adv* 2019;3:2689–2695. <https://www.ncbi.nlm.nih.gov/pubmed/31511228>
74. Eissa HM, Allen CE, Kamdar K, et al. Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? *Pediatr Hematol Oncol* 2014;31:253–257. <https://www.ncbi.nlm.nih.gov/pubmed/24087880>
75. Anoop P, Sankpal S, Stiller C, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. *Leuk Lymphoma* 2012;53:1882–1888. <https://www.ncbi.nlm.nih.gov/pubmed/22448922>
76. Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2009;52:177–181. <https://www.ncbi.nlm.nih.gov/pubmed/18816698>
77. Osumi T, Mori T, Fujita N, et al. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. *Pediatr Blood Cancer* 2016;63:1794–1799. <https://www.ncbi.nlm.nih.gov/pubmed/27314926>
78. Giulino-Roth L, Rifaort R, Kernan NA, et al. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. *Pediatr Blood Cancer* 2013;60:2018–2024. <https://www.ncbi.nlm.nih.gov/pubmed/24038967>
79. Andion M, Molina B, Gonzalez-Vicent M, et al. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. *J Pediatr Hematol Oncol* 2011;33:e89–e91. <https://www.ncbi.nlm.nih.gov/pubmed/21358341>
80. Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. *Biol Blood Marrow Transplant* 2010;16:223–230. <https://www.ncbi.nlm.nih.gov/pubmed/19800015>
81. Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? *Haematologica* 2016;101:680–687. <https://www.ncbi.nlm.nih.gov/pubmed/27252513>
82. Lee CJ, Savani BN, Mohty M, et al. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica* 2017;102:1810–1822. <https://www.ncbi.nlm.nih.gov/pubmed/28883081>
83. Levine DR, Mandrell BN, Sykes A, et al. Patients' and parents' needs, attitudes, and perceptions about early palliative care integration in pediatric oncology. *JAMA Oncol* 2017;3:1214–1220. <https://www.ncbi.nlm.nih.gov/pubmed/28278329>
84. Olagunju AT, Sarimiye FO, Olagunju TO, et al. Child's symptom burden and depressive symptoms among caregivers of children with cancers: an argument for early integration of pediatric palliative care. *Ann Palliat Med* 2016;5:157–165. <https://www.ncbi.nlm.nih.gov/pubmed/27199271>
85. Sung L, Zaoutis T, Ullrich NJ, et al. Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care. *Pediatr Blood Cancer* 2013;60:1027–1030. <https://www.ncbi.nlm.nih.gov/pubmed/23255159>
86. Anghelescu DL, Faughnan LG, Jeha S, et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2011;57:1147–1153. <https://www.ncbi.nlm.nih.gov/pubmed/21319291>
87. Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic

- stem-cell transplantation recipients: 2017 update. *J Clin Oncol* 2017;35:2082–2094. <https://www.ncbi.nlm.nih.gov/pubmed/28459614>
88. Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update [published online April 28, 2017]. *Pediatr Blood Cancer* doi: 10.1002/pbc.26542 <https://www.ncbi.nlm.nih.gov/pubmed/28453189>
 89. Sung L, Robinson P, Treister N, et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. *BMJ Support Palliat Care* 2017;7:7–16. <https://www.ncbi.nlm.nih.gov/pubmed/25818385>
 90. Robinson PD, Oberoi S, Tomlinson D, et al. Management of fatigue in children and adolescents with cancer and in paediatric recipients of haematopoietic stem-cell transplants: a clinical practice guideline. *Lancet Child Adolesc Health* 2018;2:371–378. <https://www.ncbi.nlm.nih.gov/pubmed/30169270>
 91. Diorio C, Robinson PD, Ammann RA, et al. Guideline for the management of clostridium difficile infection in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation recipients. *J Clin Oncol* 2018;36:3162–3171. <https://www.ncbi.nlm.nih.gov/pubmed/30216124>
 92. Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. *Pediatr Blood Cancer* 2016;63:1144–1151. <https://www.ncbi.nlm.nih.gov/pubmed/26960036>
 93. Kearney JA, Salley CG, Muriel AC. Standards of psychosocial care for parents of children with cancer. *Pediatr Blood Cancer* 2015; 62(S5, Suppl 5):S632–S683. <https://www.ncbi.nlm.nih.gov/pubmed/26700921>
 94. Choi EK, Yoon SJ, Kim JH, et al. Depression and distress in caregivers of children with brain tumors undergoing treatment: psychosocial factors as moderators. *Psychooncology* 2016;25:544–550. <https://www.ncbi.nlm.nih.gov/pubmed/26426911>
 95. Warner EL, Kirchhoff AC, Nam GE, et al. Financial burden of pediatric cancer for patients and their families. *J Oncol Pract* 2015;11:12–18. <https://www.ncbi.nlm.nih.gov/pubmed/25316026>
 96. Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). *Clin Microbiol Infect* 2018;24(Suppl 2):S71–S82. <https://www.ncbi.nlm.nih.gov/pubmed/29447988>
 97. Barmettler S, Ong MS, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. *JAMA Netw Open* 2018;1:e184169. <https://www.ncbi.nlm.nih.gov/pubmed/30646343>
 98. Derinkuyu BE, Boyunağa Ö, Öztunalı Ç, et al. Imaging features of Burkitt lymphoma in pediatric patients. *Diagn Interv Radiol* 2016;22:95–100. <https://www.ncbi.nlm.nih.gov/pubmed/26611257>
 99. Fallon SC, Redell MS, El-Bietar J, et al. Intestinal perforation after treatment of Burkitt's lymphoma: case report and review of the literature. *J Pediatr Surg* 2013;48:436–440. <https://www.ncbi.nlm.nih.gov/pubmed/23414881>
 100. Pession A, Masetti R, Gaidano G, et al. Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. *Adv Ther* 2011;28:684–697. <https://www.ncbi.nlm.nih.gov/pubmed/21779956>
 101. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. *N Engl J Med* 2011;364:1844–1854. <https://www.ncbi.nlm.nih.gov/pubmed/21561350>
 102. Galaray PJ, Hochberg J, Perkins SL, et al. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. *Br J Haematol* 2013;163:365–372. <https://www.ncbi.nlm.nih.gov/pubmed/24032600>
 103. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. *J Clin Oncol* 2008;26:2767–2778. <https://www.ncbi.nlm.nih.gov/pubmed/18509186>
 104. Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. *Br J Haematol* 2010;149:578–586. <https://www.ncbi.nlm.nih.gov/pubmed/20331465>

See JNCCN.org for supplemental online content.

Individual Disclosures for the NCCN Pediatric Aggressive Mature B-Cell Lymphomas Panel

Panel Member	Clinical Research Support/Data Safety Monitoring Board	Scientific Advisory Boards, Consultant, or Expert Witness	Promotional Advisory Boards, Consultant, or Speakers Bureau	Specialties
Saro Armenian, DO, MPH	None	None	None	Pediatric Oncology
Anthony N. Audino, MD	None	None	None	Pediatric Oncology
Phillip Barnette, MD	None	None	None	Pediatric Oncology
Matthew Barth, MD	None	None	None	Pediatric Oncology
Branko Cuglievan, MD	None	None	None	Pediatric Oncology
Kimberly Davies, MD	None	None	None	Pediatric Oncology
Hilda Ding, MD	Bioverativ Inc.; Bristol-Myers Squibb Company; and X4 Pharmaceuticals, Inc.	None	None	Pediatric Oncology
James B. Ford, DO	None	None	None	Pediatric Oncology
Paul J. Galaray, MD ^a	None	None	None	Pediatric Oncology
Rebecca Gardner, MD	None	Janssen Pharmaceutica Products, LP, and Novartis Pharmaceuticals Corporation	None	Pediatric Oncology
Rabi Hanna, MD	None	None	None	Pediatric Oncology, and Bone Marrow Transplantation
Robert Hayashi, MD	Maghenta	None	None	Pediatric Oncology, and Bone Marrow Transplantation
Alexandra E. Kovach, MD	None	None	None	Pathology
Andrea Judit Machnitz, MD	None	None	None	Diagnostic Radiology
Kelly W. Maloney, MD	None	None	None	Pediatric Oncology
Lianna Marks, MD	None	None	None	Pediatric Oncology
Kristin Page, MD	None	None	None	Pediatric Oncology
Anne F. Reilly, MD, MPH	None	None	None	Pediatric Oncology
Joanna L. Weinstein, MD	None	None	None	Pediatric Oncology
Ana C. Xavier, MD	None	None	None	Pediatric Oncology

The NCCN Guidelines Staff have no conflicts to disclose.

^aThe following individuals have disclosed that they have an employment/governing board, patent, equity, or royalty:

Paul J. Galaray: Abbott Laboratories, and AbbVie, Inc.